Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 443

1.

The histone acetyltransferase hMOF promotes vascular invasion in hepatocellular carcinoma.

Poté N, Cros J, Laouirem S, Raffenne J, Negrão M, Albuquerque M, Bedossa P, Godinho Ferreira M, Ait Si Ali S, Fior R, Paradis V.

Liver Int. 2020 Jan 13. doi: 10.1111/liv.14381. [Epub ahead of print]

PMID:
31943753
2.

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.

Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A.

Contemp Clin Trials. 2019 Dec 24;89:105922. doi: 10.1016/j.cct.2019.105922. [Epub ahead of print]

3.

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.

Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V.

J Hepatol. 2019 Dec 17. pii: S0168-8278(19)30721-4. doi: 10.1016/j.jhep.2019.12.008. [Epub ahead of print]

PMID:
31862486
4.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators.

Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5.

PMID:
31813633
5.

Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.

Bowlus CL, Pockros PJ, Kremer AE, Parés A, Forman LM, Drenth JPH, Ryder SD, Terracciano L, Jin Y, Liberman A, Pencek R, Iloeje U, MacConell L, Bedossa P.

Clin Gastroenterol Hepatol. 2019 Oct 10. pii: S1542-3565(19)31106-1. doi: 10.1016/j.cgh.2019.09.050. [Epub ahead of print]

PMID:
31606455
6.

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.

Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z.

Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.

7.

FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.

Rohrbach TD, Asgharpour A, Maczis MA, Montefusco D, Cowart LA, Bedossa P, Sanyal AJ, Spiegel S.

J Lipid Res. 2019 Jul;60(7):1311-1322. doi: 10.1194/jlr.M093799. Epub 2019 May 20.

PMID:
31110049
8.

Porto-sinusoidal vascular disease: proposal and description of a novel entity.

De Gottardi A, Rautou PE, Schouten J, Rubbia-Brandt L, Leebeek F, Trebicka J, Murad SD, Vilgrain V, Hernandez-Gea V, Nery F, Plessier A, Berzigotti A, Bioulac-Sage P, Primignani M, Semela D, Elkrief L, Bedossa P, Valla D, Garcia-Pagan JC; VALDIG group.

Lancet Gastroenterol Hepatol. 2019 May;4(5):399-411. doi: 10.1016/S2468-1253(19)30047-0.

PMID:
30957754
9.

Variation of fetuin-A in maternal and fetal serum during human parturition.

Albuquerque M, Luton D, Le Faouder J, Bedossa P, Guibourdenche J, Ceccaldi PF.

J Gynecol Obstet Hum Reprod. 2019 Sep;48(7):515-519. doi: 10.1016/j.jogoh.2019.02.003. Epub 2019 Feb 20.

PMID:
30794957
10.

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN.

Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042. Epub 2019 Jan 25.

PMID:
30689971
11.

Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome.

Laouirem S, Sannier A, Norkowski E, Cauchy F, Doblas S, Rautou PE, Albuquerque M, Garteiser P, Sognigbé L, Raffenne J, van Beers BE, Soubrane O, Bedossa P, Cros J, Paradis V.

Oncogene. 2019 Apr;38(16):3033-3046. doi: 10.1038/s41388-018-0597-1. Epub 2018 Dec 21.

12.

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

PMID:
30570529
13.

Evidence for an Association Between Intrahepatic Vascular Changes and the Development of Hepatopulmonary Syndrome.

Lejealle C, Paradis V, Bruno O, de Raucourt E, Francoz C, Soubrane O, Lebrec D, Bedossa P, Valla D, Mal H, Vilgrain V, Durand F, Rautou PE.

Chest. 2019 Jan;155(1):123-136. doi: 10.1016/j.chest.2018.09.017. Epub 2018 Oct 4.

PMID:
30292761
14.

Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study.

Ruggiu M, Bedossa P, Rautou PE, Bertheau P, Plessier A, Peffault de Latour R, Robin M, Sicre de Fontbrune F, Pagliuca S, Villate A, Xhaard A, Socié G, Michonneau D.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2523-2531. doi: 10.1016/j.bbmt.2018.07.037. Epub 2018 Jul 30.

15.

At similar weight loss, dietary composition determines the degree of glycemic improvement in diet-induced obese C57BL/6 mice.

Vangoitsenhoven R, van der Ende M, Corbeels K, Monteiro Carvalho Mori Cunha JP, Lannoo M, Bedossa P, van der Merwe S, Mertens A, Gesquiere I, Meulemans A, Matthys C, Mathieu C, Overbergh L, Van der Schueren B.

PLoS One. 2018 Jul 23;13(7):e0200779. doi: 10.1371/journal.pone.0200779. eCollection 2018.

16.

Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.

Mayo R, Crespo J, Martínez-Arranz I, Banales JM, Arias M, Mincholé I, Aller de la Fuente R, Jimenez-Agüero R, Alonso C, de Luis DA, Vitek L, Stritesky J, Caballería J, Romero-Gómez M, Martín-Duce A, Mugüerza Huguet JM, Busteros-Moraza JI, Idowu MO, Castro A, Martínez-Chantar ML, Ortiz P, Bruha R, Lu SC, Bedossa P, Noureddin M, Sanyal AJ, Mato JM.

Hepatol Commun. 2018 May 4;2(7):807-820. doi: 10.1002/hep4.1188. eCollection 2018 Jul.

17.

Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort).

Wendum D, Layese R, Ganne-Carrié N, Bourcier V, Merabtene F, Cagnot C, Sauce E, Barget N, Bedossa P, Terris B, Selves J, Bioulac-Sage P, Sturm N, Sattonnet C, Nahon P, Roudot-Thoraval F, Ziol M; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1534-1548. doi: 10.1002/hep.29927.

18.

Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW.

Histopathology. 2018 Sep;73(3):369-385. doi: 10.1111/his.13520. Epub 2018 May 30. Review.

PMID:
29573451
19.

In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma.

Dayot S, Speisky D, Couvelard A, Bourgoin P, Gratio V, Cros J, Rebours V, Sauvanet A, Bedossa P, Paradis V, Ruszniewski P, Couvineau A, Voisin T.

Oncotarget. 2018 Jan 9;9(6):6952-6967. doi: 10.18632/oncotarget.24084. eCollection 2018 Jan 23.

20.

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.

Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Lee HW, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J.

Aliment Pharmacol Ther. 2018 Apr;47(7):989-1000. doi: 10.1111/apt.14529. Epub 2018 Feb 15.

21.

Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential.

Bedossa P.

Liver Int. 2018 Feb;38 Suppl 1:64-66. doi: 10.1111/liv.13653. Review.

PMID:
29427497
22.

Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression.

D'Ambrosio R, Aghemo A, Rumi MG, Degasperi E, Sangiovanni A, Maggioni M, Fraquelli M, Perbellini R, Rosenberg W, Bedossa P, Colombo M, Lampertico P.

Liver Int. 2018 Aug;38(8):1459-1467. doi: 10.1111/liv.13707. Epub 2018 Mar 12.

PMID:
29377616
23.

Reply to Wang and Kan.

Beaufrère A, Guedj N, Maggiori L, Patroni A, Bedossa P, Panis Y.

Colorectal Dis. 2018 Apr;20(4):341-342. doi: 10.1111/codi.14023. No abstract available.

PMID:
29345771
24.

Functional role of ADAMTS5 in adiposity and metabolic health.

Bauters D, Bedossa P, Lijnen HR, Hemmeryckx B.

PLoS One. 2018 Jan 2;13(1):e0190595. doi: 10.1371/journal.pone.0190595. eCollection 2018.

25.

The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease.

Cazanave S, Podtelezhnikov A, Jensen K, Seneshaw M, Kumar DP, Min HK, Santhekadur PK, Banini B, Mauro AG, M Oseini A, Vincent R, Tanis KQ, Webber AL, Wang L, Bedossa P, Mirshahi F, Sanyal AJ.

Sci Rep. 2017 Dec 8;7(1):17193. doi: 10.1038/s41598-017-17370-6.

26.

Role of ADAMTS13 in diet-induced liver steatosis.

Geys L, Roose E, Vanhoorelbeke K, Bedossa P, Scroyen I, Lijnen HR.

Mol Med Rep. 2017 Aug;16(2):1451-1458. doi: 10.3892/mmr.2017.6714. Epub 2017 Jun 7.

PMID:
29067443
27.

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.

Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ; Liver Forum Case Definitions Working Group.

Hepatology. 2018 May;67(5):2001-2012. doi: 10.1002/hep.29607. Epub 2018 Feb 22.

28.

Cholangiopathy in critically ill patients surviving beyond the intensive care period: a multicentre survey in liver units.

Laurent L, Lemaitre C, Minello A, Plessier A, Lamblin G, Poujol-Robert A, Gervais-Hasenknopf A, Pariente EA, Belenotti P, Mostefa-Kara N, Sogni P, Legrand M, Cournac JM, Tamion F, Savoye G, Bedossa P, Valla DC, Vilgrain V, Goria O.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1070-1076. doi: 10.1111/apt.14367. Epub 2017 Oct 11.

29.

Circumferential margin involvement after total mesorectal excision for mid or low rectal cancer: are all R1 resections equal?

Beaufrère A, Guedj N, Maggiori L, Patroni A, Bedossa P, Panis Y.

Colorectal Dis. 2017 Nov;19(11):O377-O385. doi: 10.1111/codi.13895.

PMID:
28941054
30.

Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study.

Poté N, Cauchy F, Albuquerque M, Cros J, Soubrane O, Bedossa P, Paradis V.

Liver Int. 2018 Apr;38(4):687-694. doi: 10.1111/liv.13585. Epub 2017 Sep 24.

PMID:
28872754
31.

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos-Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Saeter G, Schrappe M, Soffietti R, Travado L, van Poppel H, Wait S, Naredi P.

Eur J Cancer. 2017 Sep;82:193-202. doi: 10.1016/j.ejca.2017.04.014. Epub 2017 Jul 7.

32.

Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy.

de Lédinghen V, Hiriart JB, Vergniol J, Merrouche W, Bedossa P, Paradis V.

Dig Dis Sci. 2017 Sep;62(9):2569-2577. doi: 10.1007/s10620-017-4638-3. Epub 2017 Jun 2.

PMID:
28577247
33.

The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass.

Bel Lassen P, Charlotte F, Liu Y, Bedossa P, Le Naour G, Tordjman J, Poitou C, Bouillot JL, Genser L, Zucker JD, Sokolovska N, Aron-Wisnewsky J, Clément K.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2443-2453. doi: 10.1210/jc.2017-00138.

PMID:
28419237
34.

Non-cirrhotic portal hypertension in necrobiotic xanthogranuloma associated with monoclonal gammopathy.

Vignon M, Placais L, Malphettes M, Bouaziz JD, Asli B, Bedossa P, Rivet J, Szalat R, Zagdanski AM, Rybojad M, Fermand JP, Baron M, Rautou PE, Arnulf B.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):e403-e405. doi: 10.1111/jdv.14213. Epub 2017 Mar 31. No abstract available.

PMID:
28295661
35.

Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice.

Verbeek J, Spincemaille P, Vanhorebeek I, Van den Berghe G, Vander Elst I, Windmolders P, van Pelt J, van der Merwe S, Bedossa P, Nevens F, Cammue B, Thevissen K, Cassiman D.

Lipids Health Dis. 2017 Feb 23;16(1):46. doi: 10.1186/s12944-017-0432-7.

36.

A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis.

Bissonnette J, Altamirano J, Devue C, Roux O, Payancé A, Lebrec D, Bedossa P, Valla D, Durand F, Ait-Oufella H, Sancho-Bru P, Caballeria J, Ginès P, Boulanger CM, Bataller R, Rautou PE.

Hepatology. 2017 Aug;66(2):555-563. doi: 10.1002/hep.29080. Epub 2017 Jun 22.

PMID:
28120471
37.

Pathology of non-alcoholic fatty liver disease.

Bedossa P.

Liver Int. 2017 Jan;37 Suppl 1:85-89. doi: 10.1111/liv.13301. Review.

PMID:
28052629
38.

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.

Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J.

J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28.

PMID:
28039099
39.

Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity.

Bedossa P, Tordjman J, Aron-Wisnewsky J, Poitou C, Oppert JM, Torcivia A, Bouillot JL, Paradis V, Ratziu V, Clément K.

Gut. 2017 Sep;66(9):1688-1696. doi: 10.1136/gutjnl-2016-312238. Epub 2016 Nov 24. Review.

PMID:
27884920
40.

Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis.

Cauchy F, Mebarki M, Leporq B, Laouirem S, Albuquerque M, Lambert S, Bourgoin P, Soubrane O, Van Beers BE, Faivre S, Bedossa P, Paradis V.

Clin Sci (Lond). 2017 Jan 1;131(1):27-36. Epub 2016 Nov 1.

PMID:
27803295
41.

MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C.

Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M, Boyer N, Vidaud M, Bedossa P, Marcellin P, Bièche I, Estrabaud E, Asselah T.

Sci Rep. 2016 Oct 12;6:34935. doi: 10.1038/srep34935.

42.

Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.

Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A, Bernstien D, Maruyama H, Saraswat V, Chawla Y, Hamid S, Abbas Z, Bedossa P, Sakhuja P, Elmahatab M, Lim SG, Lesmana L, Sollano J, Jia JD, Abbas B, Omar A, Sharma B, Payawal D, Abdallah A, Serwah A, Hamed A, Elsayed A, AbdelMaqsod A, Hassanein T, Ihab A, GHaziuan H, Zein N, Kumar M.

Hepatol Int. 2017 Jan;11(1):1-30. doi: 10.1007/s12072-016-9760-3. Epub 2016 Oct 6.

PMID:
27714681
43.

SAF score and mortality in NAFLD after up to 41 years of follow-up.

Hagström H, Nasr P, Ekstedt M, Kechagias S, Stål P, Bedossa P, Hultcrantz R.

Scand J Gastroenterol. 2017 Jan;52(1):87-91. doi: 10.1080/00365521.2016.1230779. Epub 2016 Sep 10.

44.

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T; FLIP Consortium and the FibroFrance Group.

Aliment Pharmacol Ther. 2016 Oct;44(8):877-89. doi: 10.1111/apt.13770. Epub 2016 Aug 23.

45.

Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice.

Kwanten WJ, Vandewynckel YP, Martinet W, De Winter BY, Michielsen PP, Van Hoof VO, Driessen A, Timmermans JP, Bedossa P, Van Vlierberghe H, Francque SM.

Am J Physiol Gastrointest Liver Physiol. 2016 Oct 1;311(4):G599-G609. doi: 10.1152/ajpgi.00418.2015. Epub 2016 Aug 11.

46.

AdipoScan: A Novel Transient Elastography-Based Tool Used to Non-Invasively Assess Subcutaneous Adipose Tissue Shear Wave Speed in Obesity.

Sasso M, Liu Y, Aron-Wisnewsky J, Bouillot JL, Abdennour M, Clet M, Sandrin L, le Naour G, Bedossa P, Tordjman J, Clément K, Miette V.

Ultrasound Med Biol. 2016 Oct;42(10):2401-13. doi: 10.1016/j.ultrasmedbio.2016.06.016. Epub 2016 Jul 26.

PMID:
27471115
47.

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.

Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, Vernerey D, Maire F, Lévy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A.

Endocr Relat Cancer. 2016 Aug;23(8):625-33. doi: 10.1530/ERC-16-0117. Epub 2016 Jun 28.

PMID:
27353036
48.

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.

D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M.

PLoS One. 2016 Jun 15;11(6):e0155967. doi: 10.1371/journal.pone.0155967. eCollection 2016.

49.

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.

Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min HK, Mirshahi F, Bedossa P, Sun X, Hoshida Y, Koduru SV, Contaifer D Jr, Warncke UO, Wijesinghe DS, Sanyal AJ.

J Hepatol. 2016 Sep;65(3):579-88. doi: 10.1016/j.jhep.2016.05.005. Epub 2016 May 31.

50.

ADAMTS5 deficiency protects against non-alcoholic steatohepatitis in obesity.

Bauters D, Spincemaille P, Geys L, Cassiman D, Vermeersch P, Bedossa P, Scroyen I, Lijnen HR.

Liver Int. 2016 Dec;36(12):1848-1859. doi: 10.1111/liv.13181. Epub 2016 Jul 4.

PMID:
27254774

Supplemental Content

Loading ...
Support Center